Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T63816 Target Info
Target Name Histone deacetylase 4 (HDAC4)
Synonyms KIAA0288; HD4
Target Type Clinical trial Target
Gene Name HDAC4
Biochemical Class Carbon-nitrogen hydrolase
UniProt ID
HDAC4_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
World Intellectual Property Organization (WIPO)
Patent ID WO2016179554
Title Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof.
Abstract Provided are certain histone deacetylase (HDAC) inhibitors of Formula (I), compositions thereof, and methods of their use.
Applicant(s) Chdi Foundation, Inc
Representative Drug(s) D03KOH Drug Info IC50 = 3 nM Click to Show More [1]
2 D08CYC Drug Info IC50 = 3 nM [1]
3 D0E7TU Drug Info IC50 = 21 nM [1]
Patent ID WO2016179550
Title Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof.
Abstract Provided are certain histone deacetylase (HDAC) inhibitors of Formula (I), compositions thereof, and methods of their use.
Applicant(s) Chdi Foundation, Inc
Representative Drug(s) D0O1LX Drug Info IC50 = 3 nM Click to Show More [1]
2 D0BV4M Drug Info IC50 = 8 nM [1]
Patent ID WO2014014900
Title Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof.
Abstract Provided are certain histone deacetylase (HDAC) inhibitors, compositions thereof, and methods of their use.
Applicant(s) Chdi Foundation, Inc
Representative Drug(s) D0L1NO Drug Info IC50 = 10 nM Click to Show More [1]
2 D0NG9V Drug Info IC50 = 20 nM [1]
3 D07KQB Drug Info IC50 = 40 nM [1]
4 D0SP7T Drug Info IC50 = 40 nM [1]
Patent ID WO2017039726
Title Novel Hdac Inhibitors and Methods of Treatment Using The Same.
Abstract Disclosed herein are novel HDAC inhibitors. The HDAC inhibitors may be used in methods of treating cancer. The HDAC inhibitors may be used in methods of treating a neurological disorder.
Applicant(s) Uwm Research Foundation, Inc
Representative Drug(s) D0JB4S Drug Info IC50 > 1000000 nM [1]
Patent ID WO2016018795
Title Histone Deacetylase Inhibitors.
Abstract Provided herein are brain penetrant histone deacetylase (HDAC) inhibitors useful for treating diseases or disorders associated with HDAC. An exemplary HDAC inhibitor provided herein exhibits a brain-to-plama ratio of 20: 1. Pharmaceutical compositions comprising HDAC inhibitors and methods for treating diseases associated with HDAC are also provided.
Applicant(s) The General Hospital Corporation
Representative Drug(s) D0DI9S Drug Info IC50 = 1970 nM [1]
Patent ID WO2015187542
Title Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof.
Abstract Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. The condition or disorder mediated by HDAC comprises a neurodegenerative pathology. Accordingly, also provided is a method of treating a neurodegenerative pathology mediated by HDAC in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt thereof, described herein.
Applicant(s) Chdi Foundation, Inc
Representative Drug(s) D0M7GG Drug Info IC50 = 12 nM [1]
Patent ID WO2015175813
Title Heterocyclic Hydroxamic Acids As Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof.
Abstract The present invention relates to novel hydroxamic acids which are specific histone deacetylase (HDAC) inhibitors and/or TTK/Mpsl kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating HDAC and/or TTK/Mpsl kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation.
Applicant(s) The Regents of the University of Colorado, A Body Corporate
Representative Drug(s) D0BP8I Drug Info IC50 > 100000 nM [1]
Patent ID WO2014178606
Title Novel Compounds for Selective Histone Deacetylase Inhibitors, and Pharmaceutical Composition Comprising The Same.
Abstract The present invention relates to novel urea derivatives and, more particularly, to novel urea derivatives with histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, their use for the preparation of a medicaments comprising the same, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing novel urea derivatives. The novel urea derivatives as selective histone deacetylase (HDAC) inhibitors are effective for the treatment of histone deacetylase-mediated diseases such as malignant tumors, inflammatory diseases, rheumatoid arthritis, neurodegeneration, etc.
Applicant(s) Chong Kun Dang Pharmaceutical Corp
Representative Drug(s) D0LP1K Drug Info IC50 = 16400 nM [1]
Patent ID WO2014159218
Title Histone Deacetylase Inhibitors and Compositions.
Abstract Provided are certain histone deacetylase (HDAC) inhibitors of Formula (I), compositions thereof, and methods of their use.
Applicant(s) Chdi Foundation, Inc
Representative Drug(s) D02YLT Drug Info IC50 = 55 nM [1]
Patent ID WO2014159214
Title Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof.
Abstract Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
Applicant(s) Chdi Foundation, Inc
Patent ID WO2014159210
Title Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof.
Abstract Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
Applicant(s) Chdi Foundation, Inc
Patent ID WO2013192554
Title Substituted Tropolone Derivatives and Methods of Use.
Abstract The compositions and methods described herein relate generally to substituted tropolone derivatives, which, among other features, are useful as histone deacetylase (HDAC) inhibitors.
Applicant(s) University of Connecticut
Representative Drug(s) D0GD6R Drug Info IC50 = 2.74 nM [1]
Patent ID WO2013041480
Title New Thio Derivatives Bearing Lactams As Potent Hdac Inhibitors and Their Uses As Medicaments.
Abstract The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC is responsive, and the pharmaceutical composition containing such compounds.
Applicant(s) Sigma-Tau Industrie Farmaceutiche Riunite Spa
Representative Drug(s) D07WAT Drug Info IC50 = 100 to 500 nM [1]
Patent ID WO2013005049
Title N- (2 -Aminophenyl) Benzamide Derivatives As Histone Deacetylase Inhibitors.
Abstract This invention relates to the discovery of novel compounds, or pharmaceutically acceptable salts thereof, which possess HDAC inhibitory activity. In particular, the compounds of the invention demonstrate selectivity towards Class I HDAC enzymes, and are accordingly expected to be useful for their anti-proliferative activity and in methods of treatment of the human or animal body, for example in preventing or inhibiting tumour growth and metastasis in cancers. The invention also relates to processes for the manufacture of the compounds defined herein, or pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.
Applicant(s) Cancer Research Technology Limited
Representative Drug(s) D0CH8Q Drug Info IC50 = 9220 nM [1]
United States Patent and Trademark Office (USPTO)
Patent ID US20170044185
Title Preparation of Histone Deacetylase (Hdac) Inhibitors and Methods for Use Thereof.
Representative Drug(s) D0RA0D Drug Info IC50 = 3310 nM [1]
References  Top
REF 1 HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.